WITHDRAWN: Cytomegalovirus prophylaxis with antiviral agents for solid organ transplantation (Q36884962)

16 August 2017

1 reference

retracted paper

0 references

title

WITHDRAWN: Cytomegalovirus prophylaxis with antiviral agents for solid organ transplantation (English)

1 reference

16 August 2017

main subject

organ transplantation

1 reference

C Couchoud-Heyer

1 reference

16 August 2017

publication date

1 January 1998

1 reference

Cochrane Database of Systematic Reviews

16 August 2017

published in

1 reference

16 August 2017

1 reference

16 August 2017

page(s)

CD001320

1 reference

Prospective randomized trial of efficacy of ganciclovir versus that of anti-cytomegalovirus (CMV) immunoglobulin to prevent CMV disease in CMV-seropositive heart transplant recipients treated with OKT3.

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001320.PUB2

Prophylaxis of primary cytomegalovirus disease in renal transplant recipients. A trial of ganciclovir vs immunoglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001320.PUB2

Ganciclovir prophylaxis decreases frequency and severity of cytomegalovirus disease in seropositive liver transplant recipients treated with OKT3 monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001320.PUB2

High-Dose Oral Acyclovir Reduces the Incidence of Cytomegalovirus Infection in Liver Transplant Recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001320.PUB2

The prevention of cytomegalovirus disease in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001320.PUB2

A comparison of ganciclovir and acyclovir to prevent cytomegalovirus after lung transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001320.PUB2

Failure of prophylactic ganciclovir to prevent cytomegalovirus disease in recipients of lung transplants

21 January 2018

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD001320.PUB2

Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients. A randomized controlled trial

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD001320.PUB2

Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD001320.PUB2

High-dose acyclovir compared with short-course preemptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients. A randomized trial

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD001320.PUB2

Solid organ transplantation: results and implications of acyclovir use in liver transplants

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD001320.PUB2

A Randomized, Placebo-Controlled Trial of Oral Acyclovir for the Prevention of Cytomegalovirus Disease in Recipients of Renal Allografts

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD001320.PUB2

Prevention of cytomegalovirus disease in transplant recipients

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD001320.PUB2

Cytomegalovirus prophylaxis with antiviral agents in solid organ transplantation: a meta-analysis

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD001320.PUB2

Acyclovir in preventing cytomegalovirus infection in kidney transplant recipients: a case-controlled study

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD001320.PUB2

Cytomegalovirus infection--an etiological factor for rejection? A prospective study in 242 renal transplant patients

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD001320.PUB2

A prospective randomized study of acyclovir versus ganciclovir plus human immune globulin prophylaxis of cytomegalovirus infection after solid organ transplantation

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD001320.PUB2

Reduction by combination prophylactic therapy with CMV hyperimmune globulin and acyclovir of the risk of primary CMV disease in renal transplant recipients

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD001320.PUB2

Cytomegalovirus disease after heart transplantation: is acyclovir prophylaxis indicated?

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD001320.PUB2

Controlled trial of prophylactic versus therapeutic use of ganciclovir after liver transplantation in adults

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD001320.PUB2

A prospective randomized trial comparing sequential ganciclovir-high dose acyclovir to high dose acyclovir for prevention of cytomegalovirus disease in adult liver transplant recipients

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD001320.PUB2

Cytomegalovirus prophylaxis in solid organ transplant recipients

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD001320.PUB2

A Controlled Trial of Ganciclovir to Prevent Cytomegalovirus Disease after Heart Transplantation

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD001320.PUB2

Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected].

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD001320.PUB2

Prophylactic oral ganciclovir compared with deferred therapy for control of cytomegalovirus in renal transplant recipients

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD001320.PUB2

High-dose oral acyclovir prophylaxis for primary cytomegalovirus infection in seronegative renal allograft recipients

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD001320.PUB2

Successful prophylaxis of cytomegalovirus disease after primary CMV exposure in liver transplant recipients

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD001320.PUB2

Failure of high-dose oral acyclovir with or without immune globulin to prevent primary cytomegalovirus disease in recipients of solid organ transplants

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD001320.PUB2

Use of Pooled Immunoglobulin and Acyclovir as Prophylaxis Against Cytomegalovirus Disease in Recipients of Renal Allografts

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD001320.PUB2

Identifiers

DOI

10.1002/14651858.CD001320.PUB2

1 reference

16 August 2017

1 reference